Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.

Background and Aims To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis. Method We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Co...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 111; no. 4; pp. 599 - 613
Autores principales: Roberts, Emmert, Eden Evins, A., McNeill, Ann, Robson, Debbie
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Wiley-Blackwell Apr2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113883515&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 113883515
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Apr2016
      vid: 111
      iid: 4
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        113883515
        113883515
        113883515
        10.1111/add.13236
        113883515
      ppf: 599
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.
      aug:
        au:
          Roberts, Emmert
          Eden Evins, A.
          McNeill, Ann
          Robson, Debbie
        affil: Academic Clinical Fellow in Psychiatry, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London UK
      sug:
        subj:
          Smoking Drug Therapy
          Psychiatric Patients
          Treatment Outcomes
          Nicotine Replacement Therapy
          Bupropion Administration and Dosage
          Heterocyclic Compounds Administration and Dosage
          Meta Analysis
          Systematic Review
          Human
          Embase
          CINAHL Database
          Medline
          Psycinfo
          Cochrane Library
          Descriptive Statistics
          Data Analysis Software
          Confidence Intervals
          Odds Ratio
          P-Value
          Placebos
          Adult
          Adult: 19-44 years
      ab: Background and Aims To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis. Method We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Controlled Trials from database inception to 1 December 2014 for randomized controlled trials (RCTs) published in English. We included all studies of smokers with SMI (including schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder and depressive psychoses) who were motivated to quit smoking. Pharmacotherapies included nicotine replacement therapy (NRT), bupropion and varenicline delivered as monotherapy or in combination compared with each other or placebo. The efficacy outcome was self-reported sustained smoking cessation, verified biochemically at the longest reported time-point. The tolerability outcome was number of patients discontinuing the trial due to any adverse event. Results Seventeen study reports were included, which represented 14 individual RCTs. No trials were found in patients with depressive psychoses, delusional disorder or that compared NRT monotherapy with placebo. A total of 356 and 423 participants were included in the efficacy and tolerability analyses, respectively. From the network meta-analysis, both bupropion and varenicline were more effective than placebo [odds ratio (OR) = 4.51, 95% credible interval (CrI) = 1.45-14.04 and OR = 5.17, 95% CrI = 1.78-15.06, respectively]. Data were insensitive to an assessment of varenicline versus bupropion (OR = 1.15, 95% CrI = 0.24-5.45). There were no significant differences in tolerability. All outcomes were rated by GRADE criteria as very low quality. Conclusions The limited evidence available to date suggests that bupropion and varenicline are effective and tolerable for smoking cessation in adults with serious mental illnesses.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N